Abstract
Objective To evaluate the impacts of different metastatic patterns on the prognosis of patients with invasive intraductal papillary mucinous neoplasm (IPMN). Materials and Methods All patients who were diagnosed with invasive IPMN in the Surveillance, Epidemiology, and End Results SEER database (2010–2015) were included in this study. They were grouped according to different metastatic patterns. Kaplan–Meier analysis and log-rank test were used for the comparison of their survival rates. The hazard ratio (HR) with 95% confidence interval (CI) was analyzed using the Cox proportional-hazards model. Results A total of 2264 cases were included in this study. The most common metastatic site was the liver. The patients with the nonorgan metastasis demonstrated the best survival outcomes, while those with multiple metastases showed the worst survival outcomes. As compared to the patients with isolated liver metastasis, those with isolated lung and other organ metastases showed better overall survival rates and tumor-specific survival rates. The patients with liver, lung, multiple, and other organ metastases or of age >60 years were the independent predictors of poor prognosis. Conclusions The patients with isolated lung and other organ metastases demonstrated better survival outcomes as compared to those with isolated liver metastasis. The patients with nonorgan metastasis demonstrated the best survival outcomes, while those with multiple metastases showed the worst survival outcomes. Further studies are needed to determine a highly selected subset of patients, who might benefit from surgery or chemotherapy.
Highlights
Ohashi et al first described the intraductal papillary mucinous neoplasm (IPMN) about 30 years ago [1]
E multivariate analysis revealed that the age of
As compared to the patients with isolated liver metastasis, those with isolated lung metastasis and other organ metastasis showed better OS and CSS (Table 2), which were consistent with the previous results. e proportional hazards (PH) assumption test was performed using STATA v16.0; the P
Summary
Ohashi et al first described the intraductal papillary mucinous neoplasm (IPMN) about 30 years ago [1]. Due to the innovations in imaging technology and its expanded use, pancreatic cysts are detected and the incidences of IPMNs are increasing [2]. IPMNs have become one of the most dramatic pancreatic tumors [3]. IPMNs represent 25% of all the cystic neoplasms of the pancreas, with an assumed incidence of 0.8 per 100,000 [4]. IPMNs are the most common of all the cystic tumors of the pancreas; branching IPMNs develop cancer in only 30% of the cases, but the main duct and mixed IPMNs have a 70% risk of becoming malignancies [5]. Invasive carcinomas, arising in or accompanying IPMN, can be of various types [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
